MCT2 is highly expressed in some human cancers (Supplementary Fig. 1b) and has been proposed as a biomarker for prostate cancer22, as well as having pro-tumorigenic23 and pro-metastatic24 roles in breast cancer. This evidence concerns the gene SLC16A7 and breast cancer.